Assays that measure the susceptibility of a particular viral isolate to particular antiretroviral agents help clinicians devise successful successor regimens for patients who are failing therapy
WILLIAM G. POWDERLY M.D., EDITOR-IN-CHIEF
OPTIMAL MEDICAL MANAGEMENT
By combining resistance testing with drug-level monitoring, providers will be able to individualize therapy to a degree never previously possible
ANDREW D. LUBER, PHARM.D., and W. DAVID HARDY, M.D.
AdvertisementClinical Considerations in Therapeutic Drug Monitoring
Update: Subcutaneous interleukin-2: Investigators observe dose-related increases in CD4 counts -- without increases in HIV RNA . . . Update: Treatment of lipodystrophy: Metformin reduces insulin resistance and visceral fat deposits . . . Scrub typhus and HIV co-infection: Does O. tsugamushi
inhibit syncytia formation in seropositive patients?
An advocate for people living with AIDS proves that HIV infection is no impediment to completing this country's oldest and most famous wilderness trail
Phenotype assay results -- reproduced here -- suggest a therapeutic option for a patient who has developed high-level resistance to two classes of antiretroviral agentsANDREW D. LUBER, PHARM.D.
This article was provided by San Francisco General Hospital. It is a part of the publication HIV Newsline.